Daul A, Elter-Schulz M, Poller U, Jockenhövel F, Pönicke K, Boomsma F, Man in't Veld A J, Schäfes R F, Brodde O E
Department Internal Medicine, University of Essen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Oct;352(4):429-37. doi: 10.1007/BF00172781.
Epinine (N-methyl-dopamine, the active metabolite of ibopamine), is a full agonist at dopamine (DA)-receptors and alpha- and beta-adrenoceptors. To study whether in vivo DA-receptors mediated effects can be separated from alpha- and beta-adrenoceptor effects we compared in 10 male volunteers the effects of i.v. epinine (0.5; 1; 2; 4 micrograms/kg/min for 15 min each) on DA-receptor (changes in serum prolactin)- and alpha- and beta-adrenoceptor (changes in systolic [Psyst] and diastolic blood pressure [Pdiast] and heart rate)-mediated effects with those of dopamine before and after propranolol (5 mg i.v. 45 min pre-infusion), bisoprolol (15 mg p.o. 2 h pre-infusion) and domperidone (10 mg p.o. 1 h pre-infusion). At the 0.5 and 1 microgram doses of dopamine and epinine did not effect Psyst, Pdiast and heart rate but significantly decreased prolactin levels. At the higher dose both dopamine and epinine significantly increased Psyst and heart rate, while only epinine significantly increased Pdiast. In addition, both dopamine and epinine significantly increased diuresis and natriuresis; in contrast, only dopamine, but not epinine dose-dependently increased plasma noradrenaline levels. Domperidone did not affect dopamine- and epinine-evoked blood pressure- and heart rate-changes, but antagonized their prolactin-effects (at least at the lower doses). Bisoprolol and propranolol significantly reduced dopamine-induced Psyst- and heart rate-increases to about the same extent. Propranolol enhanced epinine-induced Psyst- and Pdiast-increases while bisoprolol reduced epinine-evoked Psyst-increase but not Pdiast-increase. Epinine-induced heart rate-increase was abolished by bisoprolol and was converted into heart rate-decrease by propranolol. We concluded that in 0.5 and 1 microgram doses (plasma levels of 20-80 nmol/l)epinine acts only at DA-receptors. Thus, ibopamine in therapeutically recommended doses (3 x 100 mg/day with peak plasma epinine-levels of 50-80 nmol/l) very likely activates only DA-receptors. In higher doses, however, epinine-like dopamine-activates alpha- and beta-adrenoceptors whereby epinine has a stronger alpha-adrenoceptor agonistic activity than dopamine. Moreover, part of the dopamine-effects are indirect via release of endogenous noradrenaline whereas epinine-effects do not appear to include an indirect component.
依匹宁(N-甲基多巴胺,异波帕胺的活性代谢产物)是多巴胺(DA)受体、α和β肾上腺素能受体的完全激动剂。为了研究体内DA受体介导的效应是否能与α和β肾上腺素能受体效应相分离,我们在10名男性志愿者中比较了静脉注射依匹宁(0.5、1、2、4微克/千克/分钟,每次15分钟)对DA受体(血清催乳素变化)以及α和β肾上腺素能受体(收缩压[Psyst]、舒张压[Pdiast]和心率变化)介导的效应,以及在普萘洛尔(静脉注射5毫克,输注前45分钟)、比索洛尔(口服15毫克,输注前2小时)和多潘立酮(口服10毫克,输注前1小时)给药前后多巴胺的相应效应。在0.5和1微克剂量下,多巴胺和依匹宁对Psyst、Pdiast和心率无影响,但显著降低催乳素水平。在较高剂量下,多巴胺和依匹宁均显著升高Psyst和心率,而只有依匹宁显著升高Pdiast。此外,多巴胺和依匹宁均显著增加利尿和利钠作用;相反,只有多巴胺而非依匹宁剂量依赖性地增加血浆去甲肾上腺素水平。多潘立酮不影响多巴胺和依匹宁引起的血压和心率变化,但拮抗它们对催乳素的作用(至少在较低剂量时)。比索洛尔和普萘洛尔在很大程度上显著降低多巴胺引起的Psyst和心率升高。普萘洛尔增强依匹宁引起的Psyst和Pdiast升高,而比索洛尔降低依匹宁引起的Psyst升高,但不降低Pdiast升高。比索洛尔消除依匹宁引起的心率升高,而普萘洛尔将依匹宁引起的心率升高转化为心率降低。我们得出结论,在0.5和1微克剂量(血浆水平为20 - 80纳摩尔/升)下,依匹宁仅作用于DA受体。因此,治疗推荐剂量(每日3×100毫克,血浆依匹宁峰值水平为50 - 80纳摩尔/升)的异波帕胺很可能仅激活DA受体。然而,在较高剂量下,依匹宁类似多巴胺,激活α和β肾上腺素能受体,其中依匹宁比多巴胺具有更强的α肾上腺素能受体激动活性。此外,部分多巴胺效应是通过内源性去甲肾上腺素的释放间接产生的,而依匹宁的效应似乎不包括间接成分。